Trial reportFrontiers in endocrinology2026
Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000620. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Type 2 Diabetes Mellitus (T2D) is a metabolic disorder with increasing prevalence worldwide. Fractures are increased in people with T2D. Black patients have higher bone mineral density than White patients, suggesting the potential for distinct mechanisms for fracture within specific populations. Methods: To test whether changes to metabolism during T2D may contribute to skeletal fragility, we analyzed 465 targeted metabolites in serum collected at baseline from 571 participants (average age 62.1 years) in the Action to Control Cardiovascular Risk in Diabetes trial (ACCORD, ClinicalTrials.gov NCT00000620), a randomized clinical trial of patients with T2D. Participants with T2D were enrolled and serum was collected at baseline. These serum samples were obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center. We focused exclusively on ACCORD participants who were Black, an understudied population with regards to fracture risk. Following enrollment, participants were randomized to intensive or standard glycemia strategies, which did not affect fracture or fall risk. Using the longitudinal data from ACCORD BONE, we compared the baseline serum metabolome of participants who later fractured with those who did not fracture. Results: Individual metabolite analysis revealed circulating metabolites that were significantly different at baseline in those that fractured versus those who did not. One metabolite had both adjusted and unadjusted p-values that reached significance: 7,8-dihydrofolate, which is involved in folate-dependent one-carbon metabolism, was greater in participants who later fractured compared to those who did not fracture. Importantly, several metabolites related to the tricarboxylic acid cycle were reduced in participants who later fractured, with significant unadjusted p-values. Conclusion: In summary, the metabolic differences identified here highlight the role of altered systemic metabolism and its relationship to fracture risk. Future investigations will determine if the identified metabolites serve as predictors of fracture in patients with T2D who are not Black.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.